Profil
Dr. Eric Song is a Research Analyst at Sio Capital Management LLC.
He is covering Therapeutics.
Prior to joining, Dr. Song worked as a sell-side Research Associate covering biotechnology for Raymond James in 2017.
Prior to Raymond James, he worked as an independent investor applying value investing to biotech stocks.
He earned his Ph.D in Molecular and Cellular Pharmacology from the University of Miami in 2014, He has undergraduate degree in Clinical Pharmacology from Shenyang Pharmaceutical University.
Postes actifs de Eric Song
| Sociétés | Poste | Début |
|---|---|---|
Sio Capital Management LLC
Sio Capital Management LLC Investment ManagersFinance Sio Capital aims to invest capital in a global, healthcare-focused portfolio in order to generate attractive returns for their investors. The firm has a ‘value’ orientation with a strong attention to balance sheet quality and cash flow generation. Their long portfolios typically include growth at a reasonable price (GARP) and growth investments when attractive opportunities arise. For Sio Capital’s portfolios of short investments, they look for shorts that are ‘hyped up’ and whose valuations are predicated on expectations that the firm believes to be unattainable. | Analyst-Equity | 01/01/2018 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Sio Capital Management LLC
Sio Capital Management LLC Investment ManagersFinance Sio Capital aims to invest capital in a global, healthcare-focused portfolio in order to generate attractive returns for their investors. The firm has a ‘value’ orientation with a strong attention to balance sheet quality and cash flow generation. Their long portfolios typically include growth at a reasonable price (GARP) and growth investments when attractive opportunities arise. For Sio Capital’s portfolios of short investments, they look for shorts that are ‘hyped up’ and whose valuations are predicated on expectations that the firm believes to be unattainable. | Finance |
















